Symbols / DSGN Stock $12.53 -1.96% Design Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
DSGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Pratik Shah Ph.D.
Exch · Country NMS · United States
Market Cap 782.39M
Enterprise Value 554.44M
Income -69.79M
Sales —
FCF (ttm) -31.31M
Book/sh 3.52
Cash/sh 3.56
Employees 54
Insider 10d —
IPO Mar 29, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.31
PEG —
P/S —
P/B 3.56
P/C —
EV/EBITDA -7.07
EV/Sales —
Quick Ratio 16.97
Current Ratio 17.14
Debt/Eq 0.72
LT Debt/Eq —
EPS (ttm) -1.22
EPS next Y -1.71
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-09
ROA -20.66%
ROE -30.70%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 62.44M
Shs Float 29.20M
Insider Own 31.94%
Instit Own 61.59%
Short Float 4.75%
Short Ratio 6.68
Short Interest 2.24M
52W High 13.54
vs 52W High -7.46%
52W Low 3.10
vs 52W Low 303.54%
Beta 1.58
Impl. Vol. 3.09%
Rel Volume 1.48
Avg Volume 278.12K
Volume 412.34K
Target (mean) $14.67
Tgt Median $14.50
Tgt Low $12.00
Tgt High $18.00
# Analysts 6
Recom None
Prev Close $12.78
Price $12.53
Change -1.96%
About

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.67
Mean price target
2. Current target
$12.53
Latest analyst target
3. DCF / Fair value
$-9.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.53
Low
$12.00
High
$18.00
Mean
$14.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-16 init Jefferies — → Buy $15
2026-03-10 main RBC Capital Outperform → Outperform $14
2026-01-07 init Oppenheimer — → Outperform $18
2025-12-03 up Leerink Partners Market Perform → Outperform $14
2025-11-20 up RBC Capital Sector Perform → Outperform $13
2025-11-06 main RBC Capital Sector Perform → Sector Perform $6
2024-08-06 reit RBC Capital Sector Perform → Sector Perform $4
2024-05-07 up Piper Sandler Neutral → Overweight $12
2024-03-20 reit RBC Capital Sector Perform → Sector Perform $4
2024-03-20 reit Wedbush Neutral → Neutral $5
2023-11-14 main RBC Capital Sector Perform → Sector Perform $4
2023-08-15 down Wedbush Outperform → Neutral $6
2023-08-15 down SVB Leerink Outperform → Market Perform $6
2023-08-15 down RBC Capital Outperform → Sector Perform $7
2023-05-10 main RBC Capital — → Outperform $23
2023-05-10 main Wedbush — → Outperform $19
2023-05-04 up Goldman Sachs Sell → Neutral —
2023-03-15 reit RBC Capital — → Outperform $24
2022-12-09 main SVB Leerink — → Outperform $22
2022-12-08 main RBC Capital — → Outperform $24
News
RSS: Latest DSGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-13 WILLIAM ARSANI H. Director — 562,627 $5.25 $2,953,792
2024-12-18 PRASAD DEEPA Director — 3,806 $6.27 $23,864
2024-08-09 WILLIAM ARSANI H. Director — 814,874 $4.25 $3,463,214
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
79.47
+27.39%
62.38
-20.22%
78.19
+15.68%
67.59
Research And Development
59.13
+33.32%
44.35
-22.28%
57.06
+17.38%
48.61
Selling General And Administration
20.34
+12.78%
18.03
-14.64%
21.13
+11.31%
18.98
General And Administrative Expense
20.34
+12.78%
18.03
-14.64%
21.13
+11.31%
18.98
Other Gand A
20.34
+12.78%
18.03
-14.64%
21.13
+11.31%
18.98
Total Expenses
79.47
+27.39%
62.38
-20.22%
78.19
+15.68%
67.59
Operating Income
-79.47
-27.39%
-62.38
+20.22%
-78.19
-15.68%
-67.59
Total Operating Income As Reported
-79.47
-27.39%
-62.38
+20.22%
-78.19
-15.68%
-67.59
EBITDA
-78.84
-27.61%
-61.79
+20.43%
-77.65
-15.58%
-67.19
Normalized EBITDA
-78.84
-27.61%
-61.79
+20.43%
-77.65
-15.58%
-67.19
Reconciled Depreciation
0.62
+4.36%
0.60
+10.99%
0.54
+32.27%
0.41
EBIT
-79.47
-27.39%
-62.38
+20.22%
-78.19
-15.68%
-67.59
Net Income
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Pretax Income
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Net Non Operating Interest Income Expense
9.68
-24.38%
12.79
+12.95%
11.33
—
Net Interest Income
9.68
-24.38%
12.79
+12.95%
11.33
—
Interest Income Non Operating
9.68
-24.38%
12.79
+12.95%
11.33
—
Interest Income
9.68
-24.38%
12.79
+12.95%
11.33
—
Other Income Expense
—
—
11.33
+164.36%
4.29
Other Non Operating Income Expenses
—
—
11.33
+164.36%
4.29
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Net Income From Continuing Operation Net Minority Interest
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Net Income From Continuing And Discontinued Operation
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Net Income Continuous Operations
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Normalized Income
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Net Income Common Stockholders
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Diluted EPS
—
-0.88
+26.05%
-1.19
-4.39%
-1.14
Basic EPS
—
-0.88
+26.05%
-1.19
-4.39%
-1.14
Basic Average Shares
—
56.59
+1.08%
55.98
+0.50%
55.71
Diluted Average Shares
—
56.59
+1.08%
55.98
+0.50%
55.71
Diluted NI Availto Com Stockholders
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
226.20
-10.27%
252.09
-12.96%
289.64
-15.09%
341.14
Current Assets
223.78
-9.78%
248.04
-12.84%
284.58
-15.08%
335.12
Cash Cash Equivalents And Short Term Investments
219.84
-10.44%
245.48
-12.89%
281.80
-14.71%
330.39
Cash And Cash Equivalents
16.86
-25.29%
22.56
+6.43%
21.20
-20.00%
26.50
Other Short Term Investments
202.99
-8.94%
222.91
-14.46%
260.60
-14.25%
303.89
Receivables
1.68
+32.78%
1.26
-11.80%
1.43
+28.43%
1.11
Accrued Interest Receivable
1.68
+32.78%
1.26
-11.80%
1.43
+28.43%
1.11
Prepaid Assets
2.26
+74.00%
1.30
-3.99%
1.35
-62.57%
3.62
Other Current Assets
—
—
—
—
Total Non Current Assets
2.42
-40.32%
4.05
-19.89%
5.06
-15.94%
6.02
Net PPE
2.42
-33.29%
3.63
-21.67%
4.63
-16.73%
5.56
Gross PPE
4.68
-11.32%
5.28
-7.16%
5.69
-6.46%
6.08
Accumulated Depreciation
-2.26
-36.80%
-1.66
-56.28%
-1.06
-102.87%
-0.52
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.62
+0.00%
0.62
+0.00%
0.62
+0.00%
0.62
Construction In Progress
—
—
0.00
0.00
Other Properties
3.89
-13.73%
4.51
-8.28%
4.91
-7.41%
5.31
Leases
0.17
+13.91%
0.15
+0.00%
0.15
+0.00%
0.15
Non Current Deferred Assets
—
—
—
—
Other Non Current Assets
—
0.43
-0.70%
0.43
-6.32%
0.46
Total Liabilities Net Minority Interest
13.70
+37.05%
10.00
-16.39%
11.96
-13.53%
13.83
Current Liabilities
13.05
+54.28%
8.46
-12.06%
9.62
-10.71%
10.78
Payables And Accrued Expenses
7.53
+84.39%
4.09
-16.13%
4.87
-26.10%
6.59
Payables
2.31
+5.76%
2.19
+12.68%
1.94
-35.87%
3.02
Accounts Payable
2.31
+5.76%
2.19
+12.68%
1.94
-35.87%
3.02
Current Accrued Expenses
5.22
+174.84%
1.90
-35.20%
2.93
-17.83%
3.57
Pensionand Other Post Retirement Benefit Plans Current
4.63
+29.50%
3.58
-11.35%
4.03
+13.86%
3.54
Current Debt And Capital Lease Obligation
0.89
+11.25%
0.80
+11.73%
0.72
+11.88%
0.64
Current Capital Lease Obligation
0.89
+11.25%
0.80
+11.73%
0.72
+11.88%
0.64
Total Non Current Liabilities Net Minority Interest
0.65
-57.95%
1.53
-34.28%
2.33
-23.50%
3.05
Long Term Debt And Capital Lease Obligation
0.65
-57.95%
1.53
-34.28%
2.33
-23.50%
3.05
Long Term Capital Lease Obligation
0.65
-57.95%
1.53
-34.28%
2.33
-23.50%
3.05
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Common Stock Equity
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Capital Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Share Issued
60.40
+6.42%
56.75
+0.50%
56.47
+1.03%
55.90
Ordinary Shares Number
60.40
+6.42%
56.75
+0.50%
56.47
+1.03%
55.90
Additional Paid In Capital
509.10
+8.59%
468.83
+2.98%
455.25
+3.13%
441.42
Retained Earnings
-297.01
-30.72%
-227.21
-27.92%
-177.63
-60.36%
-110.76
Gains Losses Not Affecting Retained Earnings
0.40
-15.16%
0.47
+666.13%
0.06
+101.85%
-3.36
Other Equity Adjustments
0.40
-15.16%
0.47
+666.13%
0.06
+101.85%
-3.36
Total Equity Gross Minority Interest
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Total Capitalization
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Working Capital
210.73
-12.04%
239.58
-12.87%
274.96
-15.22%
324.34
Invested Capital
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Total Debt
1.53
-34.23%
2.33
-23.48%
3.05
-17.37%
3.69
Capital Lease Obligations
1.53
-34.23%
2.33
-23.48%
3.05
-17.37%
3.69
Net Tangible Assets
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Tangible Book Value
212.50
-12.22%
242.10
-12.82%
277.69
-15.16%
327.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-54.36
-26.11%
-43.10
+26.39%
-58.56
-14.11%
-51.32
Cash Flow From Continuing Operating Activities
-54.36
-26.11%
-43.10
+26.39%
-58.56
-14.11%
-51.32
Net Income From Continuing Operations
-69.79
-40.74%
-49.59
+25.84%
-66.86
-5.61%
-63.31
Depreciation Amortization Depletion
0.62
+4.36%
0.60
+10.99%
0.54
+32.27%
0.41
Depreciation
0.62
+4.36%
0.60
+10.99%
0.54
+32.27%
0.41
Depreciation And Amortization
0.62
+4.36%
0.60
+10.99%
0.54
+32.27%
0.41
Other Non Cash Items
0.41
+6666.67%
0.01
-81.82%
0.03
-48.44%
0.06
Stock Based Compensation
14.55
+11.30%
13.07
-0.12%
13.09
+19.80%
10.93
Change In Working Capital
3.11
+413.19%
-0.99
-236.40%
0.73
-63.45%
1.99
Change In Prepaid Assets
-1.38
-708.85%
0.23
-88.55%
1.97
+158.18%
-3.39
Change In Payables And Accrued Expense
4.49
+468.01%
-1.22
+2.17%
-1.25
-123.14%
5.38
Change In Payable
4.49
+468.01%
-1.22
+2.17%
-1.25
-123.14%
5.38
Change In Account Payable
4.49
+468.01%
-1.22
+2.17%
-1.25
-123.14%
5.38
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
22.91
-47.87%
43.95
-16.33%
52.54
+123.77%
-220.99
Cash Flow From Continuing Investing Activities
22.91
-47.87%
43.95
-16.33%
52.54
+123.77%
-220.99
Net PPE Purchase And Sale
-0.19
+43.24%
-0.34
-32.81%
-0.26
+72.11%
-0.92
Purchase Of PPE
-0.19
+43.24%
-0.34
-32.81%
-0.26
+72.11%
-0.92
Capital Expenditure
-0.19
+43.24%
-0.34
-32.81%
-0.26
+72.11%
-0.92
Net Investment Purchase And Sale
23.11
-47.84%
44.30
-16.10%
52.79
+123.98%
-220.11
Purchase Of Investment
-291.78
-26.76%
-230.18
-2.44%
-224.70
+28.21%
-313.00
Sale Of Investment
314.88
+14.72%
274.47
-1.09%
277.50
+198.74%
92.89
Net Other Investing Changes
—
—
—
0.04
Financing Cash Flow
25.74
+4917.15%
0.51
-29.14%
0.72
+208.09%
0.23
Cash Flow From Continuing Financing Activities
25.74
+4917.15%
0.51
-29.14%
0.72
+208.09%
0.23
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
24.85
0.00
—
0.00
Proceeds From Stock Option Exercised
0.89
+73.68%
0.51
-29.14%
0.72
+9.37%
0.66
Net Other Financing Charges
—
—
—
-0.43
Changes In Cash
-5.71
-518.71%
1.36
+125.72%
-5.30
+98.05%
-272.07
Beginning Cash Position
22.56
+6.43%
21.20
-20.00%
26.50
-91.12%
298.57
End Cash Position
16.86
-25.29%
22.56
+6.43%
21.20
-20.00%
26.50
Free Cash Flow
-54.55
-25.56%
-43.45
+26.13%
-58.82
-12.60%
-52.23
Interest Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-3.25
+47.52%
-6.20
-1.87%
-6.08
-335.82%
-1.40
Common Stock Issuance
24.85
0.00
—
0.00
Issuance Of Capital Stock
24.85
0.00
—
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category